Tislelizumab plus chemotherapy sequential neochemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
第一作者机构：[1]UESTC, Sichuan Canc Hosp & Inst, Thorac Surg, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China
推荐引用方式(GB/T 7714)：
He W.,Wang C.,Wu L.,et al.Tislelizumab plus chemotherapy sequential neochemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)[J].ANNALS OF ONCOLOGY.2023,34:S860-S860.doi:10.1016/j.annonc.2023.09.1441.
APA：
He, W.,Wang, C.,Wu, L.,Wan, G.,Han, Y....&Peng, L..(2023).Tislelizumab plus chemotherapy sequential neochemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT).ANNALS OF ONCOLOGY,34,
MLA：
He, W.,et al."Tislelizumab plus chemotherapy sequential neochemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)".ANNALS OF ONCOLOGY 34.(2023):S860-S860
医学